Early Enteral Nutritional Supplementation on Patients With Oral and Oropharyngeal Cancer Undergoing Radio(Chemo)Therapy After Surgical
A Prospective, Randomized, Clinical Study to Evaluate the Effects of Early Enteral Nutritional Supplementation on Clinical Outcomes in Patients With Oral and Oropharyngeal Cancer Undergoing Radio(Chemo)Therapy After Surgical Resection
1 other identifier
interventional
110
1 country
1
Brief Summary
The target population in the present study is Chinese patients with oral and oropharyngeal cancer who plan to receive radio(chemo)therapy after surgical resection in the outpatient department. Investigators hypothesize that early enteral nutrition intervention, which is initiated 2 weeks before the start of postoperative radio(chemo)therapy treatment and added on demand during radiotherapy, will improve patients' nutritional status, tolerability to the radio(chemo)therapy, quality of life, and other clinical outcomes compared to commencement of oral nutritional supplements during the course of irradiation treatment. There are two cohorts in this trial, cohort 1 included patients with oral nutritional supplements and cohort 2 included patients with tube feeding (nasogastric tube or percutaneous endoscopic gastrostomy).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_2
Started Jun 2017
Longer than P75 for phase_2
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2017
CompletedFirst Submitted
Initial submission to the registry
March 21, 2018
CompletedFirst Posted
Study publicly available on registry
June 4, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 31, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
June 30, 2022
CompletedDecember 18, 2023
August 1, 2020
3.4 years
March 21, 2018
December 12, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
Body weight
changes of body weight from baseline to Final Visit/Exit.
10 weeks
Secondary Outcomes (20)
Body weight
2weeks,5 weeks, 8 weeks
Body Mass Index
10 weeks
Calf circumference by measure
5weeks, 10 weeks
Lean mass measured by Bioelectrical impedance analysis (BIA)
5weeks 10 weeks
Fat mass measured by Bioelectrical impedance analysis (BIA)
5weeks 10 weeks
- +15 more secondary outcomes
Study Arms (4)
Cohort 1-intervention
EXPERIMENTALOral supplements are given through oral route 2 weeks before radiotherapy.
Cohort 1-Control
ACTIVE COMPARATOROral supplements are given through oral route on demand during radiotherapy.
Cohort 2- Intervention
EXPERIMENTALOral supplements are given by tube feeding 2 weeks before radiotherapy.
Cohort 2- Control
ACTIVE COMPARATOROral supplements are given by tube feeding on demand during radiotherapy.
Interventions
Early nutritional intervention (Ensure) was given two weeks before radiotherapy. Ensure 3 times per day, Mixing 55.8 g or 6 spoons of Ensure with 190 mL of warm water.
Eligibility Criteria
You may qualify if:
- Subject is male or female, between 18 and 70 years old;
- Subject has clinical or radiological diagnosis of oral cancer (stage III and stage IV), had surgical resection 3 or 4 weeks prior to radio (chemo)therapy, and plans to receive radio (chemo)therapy treatment;
- Subject has Karnofsky Performance Score (KPS) ≥ 60 and an expected life expectancy ≥ 6 months;
- Subject is willing to comply with the study protocol, able and willing to consume study product according to the protocol;
- Subject has voluntarily signed and dated the informed consent form (ICF), approved by an Institutional Review Board (IRB) / Independent Ethics Committee (IEC) prior to any participation in the study
You may not qualify if:
- Except for oral cancer and oropharyngeal cancer, subject has malignant tumors or serious infectious diseases, such as tuberculosis activity, respiratory system, cardiovascular system, urinary system diseases, systemic edema and ascites caused by diseases, etc., cannot participant in study in the opinion of study physician.
- Subject has dysfunction of liver, kidney or gallbladder, cannot participant in study in the opinion of study physician.
- Subject has gastrointestinal diseases to cannot tolerate enteral nutrition (such as intestinal bleeding, intestinal obstruction, severe digestive malabsorption, severe nausea and vomiting and diarrhea) that preclude his or her participation in the opinion of study physician;
- Subject has diabetes
- Subject has known history of allergy or intolerance to any ingredient in the investigational product;
- Female subjects are pregnant or plan to get pregnant within a year or are postpartum and non-lactating;
- Subject has mental illness, cannot understand ICF, unwilling to provide informed consent.
- Subject has amputation or implanted electronic devices or metal, it may be inappropriate to use BIA to measure body composition
- Subject is currently or has participated in any clinical trial 2 months prior to enrollment.
- Subject plans to take nutritional supplements and/or traditional Chinese medicine regularly during study in the opinion of study physician. Multi-vitamin and multi-mineral supplements are exception.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Shanghai ninth people's hospital
Shanghai, Shanghai Municipality, 200011, China
Related Publications (1)
Jiang W, Zhang H, Dou S, He Y, Zhu G, Li R. Effectiveness of Early Oral Nutritional Supplementation in Preventing Weight Loss in Head and Neck Cancer Patients Undergoing Postoperative Radiotherapy or Chemoradiotherapy: A Prospective Randomized Controlled Trial. J Am Nutr Assoc. 2025 Aug;44(6):498-507. doi: 10.1080/27697061.2025.2458277. Epub 2025 Feb 4.
PMID: 39903480DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Guopei Zhu
Shanghai 9th people hospital
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Director
Study Record Dates
First Submitted
March 21, 2018
First Posted
June 4, 2018
Study Start
June 1, 2017
Primary Completion
October 31, 2020
Study Completion
June 30, 2022
Last Updated
December 18, 2023
Record last verified: 2020-08